Emergent BioSolutions | EBS - Gross Profit On Sales


Emergent BioSolutions reported $10M in Gross Profit on Sales for its fiscal quarter ending in March of 2023.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 243.27M 14.49M Mar/2026
Akebia Therapeutics USD 47.28M 1.7M Dec/2025
ALKERMES USD 331.33M 7M Mar/2026
Alnylam Pharmaceuticals USD 825M 4.3M Mar/2026
Amarin USD 23.17M 961K Dec/2025
ANI Pharmaceuticals USD 124.18M 12.39M Dec/2025
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Coherus Biosciences USD 8.7M 853K Dec/2025
Exelixis USD 590.86M 18.68M Mar/2026
Glaxosmithkline GBP 5.75B 2.99B Mar/2026
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Ionis Pharmaceuticals USD 243M 48M Mar/2026
Ironwood Pharmaceuticals USD 85.24M 44.1M Jun/2025
Lexicon Pharmaceuticals USD 5.29M 8.88M Dec/2025
Lonza CHF 1.29B 248M Jun/2025
Merck USD 10.85B 2.57B Dec/2025
Moderna USD -566M 792M Mar/2026
Myriad Genetics USD 146.8M 3M Dec/2025
Nektar Therapeutics USD 21.81M 8.06M Dec/2025
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Pacira USD 126.64M 15.61M Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Sanofi EUR 8.45B 1.31B Dec/2025
Sarepta Therapeutics USD 621.34M 577.79M Mar/2026
United Therapeutics USD 315.5M 286.6M Dec/2025
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024
Xoma 992K 846K Jun/2024